You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD-1 antibodies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Immunotherapy in MSI-H Metastatic Colorectal Cancer

Recruiting
  • Colorectal Cancer
  • Carpi, Modena, Italy
    Ospedale Ramazzini
Sep 5, 2022

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Recruiting
  • Hepatocellular Carcinoma
  • Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jul 23, 2021

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Mar 28, 2022

Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)

Not yet recruiting
  • Melanoma
  • +16 more
  • Darlinghurst, New South Wales, Australia
  • +3 more
May 12, 2023

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors Trial in Beijing (Chidamide, Decitabine, Immune checkpoint

Recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Advanced Solid Tumors
  • Beijing, Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Apr 8, 2022

Open-label, Uncontrolled, Non-Interventional, Retrospective

Recruiting
  • Melanoma
  • Lung Cancer
  • Edegem, Belgium
    Universitair Ziekenhuis Antwerpen
Apr 23, 2021

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston (biological,

Recruiting
  • Advanced Bladder Carcinoma
  • +34 more
  • Atezolizumab
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Neuroblastoma Trial in Madison, Southampton, London (Nivolumab, Ch14.18/CHO)

Recruiting
  • Neuroblastoma
  • Madison, Wisconsin
  • +2 more
Mar 28, 2022

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 Trial in Canada,

Active, not recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • +5 more
  • Anetumab Ravtansine
  • +5 more
  • Birmingham, Alabama
  • +44 more
Feb 2, 2023

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

PD-1 Antibody, DC-Cell, NK-Cell Trial (Pembrolizumab, Nivolumab, Sintilimab)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • (no location specified)
Jul 14, 2022

Anti-Argonaute Antibodies for Diagnosis of Sensory

Completed
  • Autoimmune Diseases
  • Diagnosis of sensitive neuronopathy - phase 1
  • +4 more
  • Saint-Étienne, France
    CHU Saint-Etienne
Jul 27, 2023